ClinicalTrials.gg
RecruitingNCT06171659Updated Jul 17, 2026

FDG PET/MR Imaging of Peripheral Pain Generators

An observational study in Pain and Nociceptive Pain, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Primary conditionNociceptive PainRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nociceptive Pain
Why
  1. The study's listed conditions name Nociceptive Pain, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Wisconsin, Madison · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
128
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Nociceptive Pain with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Nociceptive Pain · United States.

Started
2024
with 4 others
Observational
4 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies in Nociceptive Pain with a site in United States, this one is one of 5 that started in 2024, is one of 4 observational ones, and was the 13th registered.

Nociceptive Pain

97 studies on the registry are indexed under Nociceptive Pain; 19 are open to participants now.

Browse Nociceptive Pain studies →

Open to participants now

2 of the 16 studies in Nociceptive Pain with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Nociceptive Pain studies recruiting now, 5 (42%) set no upper age limit and 4 (33%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Nociceptive Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to determine if a PET/MRI scan using FDG can accurately identify the source of chronic pain. Identifying the source of pain may help doctors treat chronic pain more effectively. Approximately 128 participants will be enrolled and can expect to be on study for up to 12 months.

Read the detailed description

The investigators aim to precisely localize sites of increased inflammation and potentially pain generation and improve understanding of nociception and inflammation using a unique, hybrid PET/MRI approach in conjunction with intravenously, administered fluorodeoxyglucose (FDG), which has been shown with PET imaging to be an sensitive surrogate marker of inflammation.

The Primary Objective of this pilot prospective, observational research is to determine whether this approach, which combines PET/MRI and an FDA-approved radiotracer, 18F-Fluorodeoxyglucose (FDG), can accurately localize the sites of painful inflammation in individuals with persistent pain.

  • Determine if increased FDG uptake on PET as measured by standard uptake value (SUV) or target-to-background (TTB) measurements is increased in area of pain symptoms when compared to same corresponding areas in healthy, asymptomatic volunteers.
  • Determine whether amount of FDG uptake as measured on PET is able to localize to abnormalities when compared to MR imaging (T2 signal intensity, morphologic aberrations)

Secondary Objectives:

  • Verify that the standard administered adult dose of FDG (0.14 mCi/kg/patient) used currently in the clinics can also be used to detect peripheral pain generators.
  • Verify that FDG uptake in asymptomatic, healthy controls will be significantly less than their chronic pain cohorts at the same anatomic location.
  • Determine whether longitudinal FDG PET/MR imaging findings in individual patients directly correlate with symptoms as they evolve over time in joint arthroplasty subjects with PPSP.
  • Determine if FDG PET/MR imaging findings spatially differ between different pain types.
03

Conditions studied

  • Pain
  • Nociceptive Pain

Browse trials for

04

In context

Nociceptive Pain Reclassified

97 studies on the registry are indexed under Nociceptive Pain; 19 are open to participants now.

This study's planned enrollment of 128 is above the median of 74 across 32 observational studies indexed under Nociceptive Pain.

Browse Nociceptive Pain studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Compared within Nociceptive Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with persistent post-surgical pain and asymptomatic individuals who have undergone joint arthroplasty (hip or knee) or joint arthroscopy (hip or knee).

Eligibility criteria

Inclusion Criteria: Persistent Post-Surgical Pain Patients

  • 18-85 years old
  • Presents with persistent pain with pain score of ≥4 on Numerical Rating Scale [0:10] for at least 6 months following joint arthroplasty or arthroscopy.
  • Able and willing to provide
  • Willing and able to undergo PET/MRI (arthroplasty and arthroscopy participants) and PET/CT (arthroplasty participants only)

Inclusion Criteria: Asymptomatic controls

  • 18-85 years old
  • Asymptomatic (pain score of ≤2 on the NRS) for at least 6 months following joint arthroplasty or arthroscopy.
  • Able and willing to provide informed consent
  • Willing and able to undergo PET/MRI

Exclusion Criteria:

  • Inability to understand and communicate with the investigators to complete the study-related questionnaires.
  • Any co-morbidity which results in severe systemic disease limiting function as defined by the American Society of Anesthesiology (ASA) physical status classification > 3, such as the presence of current or past (6 months) pulmonary, hepatic, renal disease, arthritis, hematopoietic, and neurological diseases not related to chronic pain.
  • Pregnant or breastfeeding. (Individuals with will be asked to verbally confirm they are not pregnant. If they cannot confirm, they will have a urine pregnancy test either at the imaging study visit or within 7 days prior to the imaging study visit.)
  • Subject with (s) to or inability to undergo PET/MRI
  • Current diagnosis of of any kind. Participants in remission for at least two years and not undergoing any treatment may be considered per investigator discretion
  • Current enrollment in a scientific interventional or treatment study.
  • Subject unable or unwilling to provide informed consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
128 participants (estimated)
Patient registry
No

Groups and cohorts

  • Open Surgical Procedure (Arthroplasty)

    PPSP subjects who have undergone hip (or knee) joint arthroplasty (i.e., open surgical procedure for joint replacement). * 6 month post-op scans * 12 month post-op scans * 18 month post-op scans

    Drug: FDG radiotracer · Device: PET/MRI · Device: PET/CT imaging

  • Less Invasive Procedure (Arthroscopy)

    PPSP subjects who have undergone hip (or knee) arthroscopy (i.e., less invasive joint surgical procedure involving scopes and lower profile surgical tools) \- 6 month post-op scans

    Drug: FDG radiotracer · Device: PET/MRI

  • Asymptomatic: Had Total Joint Replacement (Arthroplasty)

    Asymptomatic subjects who have undergone total hip or total knee arthroplasty. \- single scan during one study visit (up to 3.5 hours)

    Drug: FDG radiotracer · Device: PET/MRI

  • Asymptomatic: Less Invasive Procedure (Arthroscopy)

    Asymptomatic subjects who have undergone hip or knee arthroscopy. \- single scan during one study visit (up to 3.5 hours)

    Drug: FDG radiotracer · Device: PET/MRI

Interventions

  • DrugFluorodeoxyglucose F18Studies of Fluorodeoxyglucose F18Fluorodeoxyglucose F18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.

    Also known as: fluorodeoxyglucose, 18F-Fluorodeoxyglucose

  • DevicePET/MRI

    positron emission tomography and magnetic resonance imaging

  • DevicePET/CT imaging

    positron emission tomography and computed tomography imaging

07

What researchers measure

Primary outcomes

  1. Change in SUVmax (chronic pain)

    Time frame: baseline (6 months post-op), 12 months post-op, 18 months post-op

  2. SUVmax (chronic pain vs healthy)

    Time frame: baseline

  3. Location of Pain Compared to Target-to-Background (TTB) or SUVmax

    Time frame: baseline

Secondary outcomes

  1. Number of Participants Where Standard FDG dose was sufficient to detect region of pain (symptomatic groups)

    The standard administered adult dose of FDG currently used in clinics is 0.14 mCi/kg/patient.

    Time frame: baseline

  2. Variation of the maximum ratio of SUV (SUVRmax) in asymptomatic controls vs symptomatic

    Time frame: baseline

  3. Variation of the maximum ratio of SUV (SUVRmax) in symptomatic participants

    Time frame: baseline (6 months post-op), 12 months post-op, 18 months post-op

  4. Radiology Review Scores

    Radiologists will evaluate MRI and CT images from each exam, and assign 1 point to any abnormality detected in the following compartments: prosthesis itself, bone, joint space, joint capsule, muscle, subcutaneous fat, and skin, for a total of 7 possible points. Differences in scoring from MRI vs CT images will be further investigated with a t-test.

    Time frame: up to 18 months post-op

  5. Change in Pain Scores (chronic pain)

    Pain will be evaluated on a scale of 0 (no pain) to 10 (worse possible pain).

    Time frame: baseline (6 months post-op), 12 months post-op, 18 months post-op

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2028, 43 months after the start.

Of 20 observational studies under Nociceptive Pain, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 15, 2023
StartActual
Nov 19, 2024
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06171659
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Arthroscopy Association of North America
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Nov 19, 2024
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Radiology Studies
Contact
Radstudy@uwhealth.org
608-282-8349
Sandip Biswal, MD
principal investigator · University of Wisconsin, Madison

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion